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The death-inducing receptor Fas is activated when
cross-linked by the type II membrane protein Fas ligand
(FasL). When human soluble FasL (sFasL, containing
the extracellular portion) was expressed in human em-
bryo kidney 293 cells, the three N-linked glycans of each
FasL monomer were found to be essential for efficient
secretion. Based on the structure of the closely related
lymphotoxin a-tumor necrosis factor receptor I com-
plex, a molecular model of the FasL homotrimer bound
to three Fas molecules was generated using knowledge-
based protein modeling methods. Point mutations of
amino acid residues predicted to affect the receptor-
ligand interaction were introduced at three sites. The
F275L mutant, mimicking the loss of function murine
gld mutation, exhibited a high propensity for aggrega-
tion and was unable to bind to Fas. Mutants P206R,
P206D, and P206F displayed reduced cytotoxicity to-
ward Fas-positive cells with a concomitant decrease in
the binding affinity for the recombinant Fas-immuno-
globulin Fc fusion proteins. Although the cytotoxic ac-
tivity of mutant Y218D was unaltered, mutant Y218R
was inactive, correlating with the prediction that Tyr-
218 of FasL interacts with a cluster of three basic amino
acid side chains of Fas. Interestingly, mutant Y218F
could induce apoptosis in murine, but not human cells.
The Fas ligand (CD95 ligand) is a 40-kDa type II membrane
protein belonging to the tumor necrosis factor (TNF)1 family of
proteins (1, 2). This family consists of trimeric ligands that
induce defined cellular responses upon binding to their respec-
tive receptors. Fas and the other members of the TNF receptor
family are type I membrane proteins. They are characterized
by the presence of cysteine-rich motives conferring an elon-
gated structure to their extracellular domains (1).
The Fas ligand is one of the major effectors of CD81 cytotoxic
T lymphocytes (3, 4) and natural killer cells (5). It is also
involved in the establishment of peripheral tolerance (6), in the
activation-induced cell death of lymphocytes (7–10), and in the
delimitation of immunoprivileged regions such as the eye and
testis (11, 12). Along the lines of this latter feature, cotrans-
plantation of myoblasts engineered to express FasL can protect
an islet allograft from rejection (13). The loss of function due to
mutations in murine Fas ligand (gld), murine Fas (lpr), human
Fas, or human FasL leads to lymphoproliferation, lymphade-
nopathy, and autoimmune diseases (14–18). Fas-null mice
have a similar but more severe phenotype (19).
The Fas-FasL system is implicated in a number of pathogen-
esis. Abnormally elevated levels of soluble Fas ligand are de-
tected in leukemia/lymphomas of T and natural killer cells, and
in an aggressive nasal lymphoma (20, 21). Various tumor cells
express FasL, therefore potentially creating their own immu-
noprivileged sites (22–24). The Fas/Fas ligand system is also
involved in the CD41 T cell deletion observed in human immu-
nodeficiency virus-infected individuals (25–27), in multiple
sclerosis (28), and in acute graft-versus-host disease (29, 30).
Membrane-bound Fas ligand can be processed into a soluble
form by a metalloprotease whose inhibitor profile is similar to
that of the protease solubilizing TNFa (20, 31–34). The soluble
forms of the TNF family members that have been crystallized
so far include TNFa (35), lymphotoxin a (also known as TNFb)
(36), and CD40L (37). They all share a similar conformation
resulting in a compact, pear-shaped trimeric structure. Other
family members (Fas ligand (38), TRAIL (39), CD30L, CD27L,
OX40L, and 4–1BBL) show clear sequence homology at the
amino acid level, and there is little doubt that they are all
trimeric.
In this study, we produce biologically active human soluble
Fas ligand (sFasL) and amino acid residues essential for the
Fas/FasL interaction are identified. We also demonstrate the
importance of extensive N-glycosylation for the efficient secre-
tion of FasL.
EXPERIMENTAL PROCEDURES
Materials
The anti-flag M2 monoclonal antibody and the anti-flag M2 antibody
coupled to agarose were purchased from Integra Biosciences (Wall-
isellen, Switzerland). Protein A-Sepharose was purchased from Phar-
macia (Uppsala, Sweden). Tunicamycin and Protein A were obtained
from Sigma (Buchs, Switzerland). Peptide N-glycanase F was pur-
chased from New England Biolabs (Schwalbach, Germany). The PCR-2
TA cloning vector and PCR-3 mammalian expression vector were ob-
tained from InvitroGen (NV Leek, the Netherlands). Cell culture media
and antibiotics were obtained from Life Sciences (Basel, Switzerland).
The non-radioactive cell proliferation assay was purchased from Pro-
mega (Wallisellen, Switzerland). The fusion protein muFas-Fc was
kindly provided by Dr. C. A. Smith (Immunex, Seattle, WA).
Cells
Murine B lymphoma A20 cells were grown into DMEM containing
5% heat-inactivated fetal calf serum (FCS) and the human T lympho-
blastoma Jurkat cell line was grown in RPMI supplemented with 10%
FCS. Human embryonic kidney 293 cells (ATCC CRL 1573) were cul-
tured in DMEM:nutrient mix F-12 (1:1) supplemented with 2% FCS.
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Human embryonic kidney 293 cells stably transfected with the large T
antigen of SV40 (293T cells, kindly provided by Dr. M. E. Peters,
German Cancer Research Center, Heidelberg, Germany) were grown in
DMEM supplemented with 10% FCS. All media contained antibiotics
(penicillin and streptomycin at 5 mg/ml each and neomycin at 10 mg/ml).
Expression Vectors for the Recombinant sFasL and the Soluble
Human Fas-Human Immunoglobulin Fc Chimera
sFasL—A DNA fragment coding for the signal peptide of hemaglu-
tinin, including 6 bases of its 59-untranslated sequence (40), the flag
epitope (41), a linker (GPGQVQLQ), and the PstI, SalI, XhoI, and
BamHI restriction sites, was cloned between the HindIII and BamHI
sites of a modified PCR-3 vector in which nucleotides 720–769 had been
deleted. This plasmid was called pHAflag-038. The full-length cDNA of
human Fas ligand was amplified by PCR from the cDNA of activated
peripheral blood lymphocytes (oligonucleotides: 59-CCTCTACAGGACT-
GAGAAGAAG-39 and 59-CAACATTCTCGGTGCCTGTAAC-39), and
cloned into PCR-2 TA cloning vector. This plasmid was used as PCR
template for the amplification of a portion of the extracellular domain of
the FasL (amino acids 139–281) with suitable restriction sites added at
each end. The resulting PstI/EcoRI fragment was inserted into
pHAflag-038, in frame with the flag sequence.
For each point mutation, a set of complementary oligonucleotides
containing the target mutation was used. In the first round of the PCR,
two products were produced with pHAflag-FasL as template using: (a)
the forward oligonucleotide and Sp6 primer, and (b) the reverse oligo-
nucleotide and T7 primer. Purified PCR products, containing the 39 and
59 portions of FasL, respectively, were mixed and allowed to undergo
three cycles of PCR before amplification with T7 and Sp6 primers. The
PstI/EcoRI fragment of the resulting PCR product was cloned into
pHAflag-038.
hFas-Fc—The extracellular domain of hFas (GenBank X63717, nu-
cleotides 224 to 510, the A of ATG being nucleotide 1) with 59 HindIII
and 39 SmaI sites was amplified by PCR from a full-length cDNA clone
(kindly provided by Prof. P. H. Krammer, German Cancer Research
Center, Heidelberg). The HindIII-SmaI fragment was cloned between
the HindIII and EcoRV sites of a modified PCR-III vector containing an
added SalI site after the existing EcoRV site. A SalI/NotI cDNA cassette
encoding the hinge, CH2, and CH3 domains (amino acid residues 231–
447) of human IgG1 (42) was cloned in frame at the 39 end of the
extracellular domain of Fas. Both strands of each construct were
checked by sequencing.
Expression of sFasL and hFas-Fc
Plasmids were either expressed transiently in 293T cells or stably in
293 cells. Plasmids (10 mg) were transfected by the calcium phosphate
method (3 3 105 cells/28-cm2 plate) in HEPES buffer (43). After trans-
fection, cells were grown for 48–72 h in serum-free Opti-MEM medium,
and supernatants were harvested. Stably transfected 293 cells were
obtained by selection in 800 mg/ml G418 (70% active) for 2 weeks and
cloned at that stage. Supernatants of stably transfected clones were
harvested after 10–12 days in culture and screened by Western blotting
or receptor binding ELISA (see below) for expression levels.
Peptide N-Glycanase F Digestion of sFasL
293 cells (2 3 105) transiently transfected with sFasL and their
corresponding supernatants (20 3 concentrated, 15 ml) were heated in
20 ml of 0.5% SDS, 1% 2-mercaptoethanol for 3 min at 95 °C. Samples
were cooled and supplemented with 10% Nonidet P-40 (2 ml) and 0.5 M
sodium phosphate, pH 7.5 (2 ml). Peptide N-glycanase F (125 units/ml, 1
ml) was added (or omitted in controls), and samples were incubated for
3 h at 37 °C prior to analysis by Western blotting.
Purification of sFasL and hFas-Fc
Supernatants of stably transfected cells were filtered using a
0.22-mm membrane and loaded as 40-ml aliquots onto 1-ml columns of
anti-flag M2 agarose (for sFasL) or Protein A-Sepharose (for hFas-Fc)
equilibrated in PBS. The columns were washed with 10 ml of PBS and
eluted with 2.5 ml of 50 mM citric acid. The eluate was neutralized with
1 M Tris base, concentrated, and exchanged into PBS using Cen-
triprep-30 concentrators. Protein concentration was determined by the
bicinchoninic acid method (Pierce) using bovine serum albumin as the
standard, and the purity of the samples was assessed by SDS-PAGE
and Coomassie Blue staining.
SDS-PAGE and Western Blotting
SDS-PAGE and Western blotting were performed on 12% mini gels
according to previously published methods (44, 45). Blots were incu-
bated with anti-flag M2 monoclonal antibodies (5 mg/ml, 0.02% NaN3, in
blocking buffer: PBS, 0.5% Tween 20, 4% skim milk), followed by rabbit
anti-mouse immunoglobulins coupled to horseradish peroxidase (dilut-
ed 1:2000 in blocking buffer). Peroxidase activity was detected by en-
hanced chemiluminescence.
Inhibition of N-Glycosylation with Tunicamycin
Tunicamycin was stored at 270 °C at a concentration of 1 mg/ml in
10 mM Tris-HCl, pH 9. Stably transfected cells secreting sFasL were
grown for 10 days in the presence of 1, 100, or 1000 ng/ml tunicamycin.
Cells and supernatants were harvested and analyzed by Western
blotting.
Cytotoxic Assay
A20 or Jurkat cells (100 ml, 50,000 cells, in 96-well plates) were
incubated at 37 °C in the presence of sFasL at the indicated concentra-
tions and 1 mg/ml M2 monoclonal antibody. In some experiments,
hFas-Fc or muFas-Fc was added at the indicated concentrations in the
presence of 1 mg/ml Protein A. Four to 8 h after the addition of FasL, 20
ml of a solution containing 2 mg/ml 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS) reagent (Promega) and 50 mg/ml phenazine methosulfate was
added to the cells. Following color development (2–4 h), absorbance at
490 nm was taken with an ELISA reader.
In Vitro Fas-FasL Binding Assay
96-well ELISA plates (Nunc Maxisorp) were coated with either
hFas-Fc or muFas-Fc (1 mg/ml in PBS, 100 ml, 2 h, 37 °C). The following
incubation and washing steps were performed: (a) saturation in block
buffer (PBS, 5% FCS, 300 ml, 1 h, 37 °C), (b) three washes (PBS, 0.05%
Tween-20), (c) incubation with sFasL (10–1000 ng/ml in PBS contain-
ing 50 mg/ml bovine serum albumin, 100 ml, 1 h, 37 °C), (d) three
washes, (e) incubation with M2 monoclonal antibody (1 mg/ml in block
buffer, 100 ml, 37 °C, 30 min), (f) three washes, (g) incubation with
rabbit anti-mouse IgG coupled to peroxidase (1/1000 dilution in block
buffer, 100 ml, 30 min, 37 °C), (h) three washes, (i) detection (0.3 mg/ml
o-phenylenediamine hydrochloride, 0.01% H2O2 in 50 mM citric acid,
100 mM Na2HPO4, 200 ml, as necessary (1–5 min), 25 °C), and (j)
termination (2 N HCl, 50 ml). Absorbance was taken at 490 nm with an
ELISA reader.
Gel Permeation Chromatography
sFasL samples (5 mg in 100 ml) were mixed with the internal stand-
ards catalase and ovalbumin, then loaded onto a Superdex-200
HR10/30 column, and the proteins were eluted in PBS at 0.5 ml/min.
Fractions (0.25 ml) were analyzed using the receptor binding ELISA
(using 5 ml of fractions for active ligands), and Western blotting was
carried out after trichloroacetic acid precipitation of the entire fraction.
The column was calibrated with standard proteins: thyroglobulin (669
kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), bovine
serum albumin (67 kDa), ovalbumin (43 kDa), chymotrypsinogen A (25
kDa), and ribonuclease A (13.7 kDa).
Protein Modeling
Molecular models for both Fas and FasL were generated using
knowledge-based protein modeling methods as implemented in the
Swiss-Model server (46, 47). A molecular model for FasL was built using
the known tridimensional structures of both TNFa (48) and lympho-
toxin a (TNFb) (49) (Protein Data Bank entries 1TNF and 1TNR chains
A, B, and C) (50). The known structure of the 55-kDa tumor necrosis
factor receptor (51) was used to produce a molecular model for Fas. In
both cases, the modeling procedure was started by submitting the
respective protein sequences to Swiss-Model via the First Approach
Mode. The resulting models were then used to correct the automated
multiple sequence alignments generated by the server in several loop
regions. These corrected alignments were resubmitted to Swiss-Model
through the Optimize Mode. The resulting models were structurally
sound, and did not show obvious sequence or structure inconsistencies
(51) according to three-dimensional/one-dimensional profiles (52) and
ProsaII (53). The quaternary structure of the Fas-FasL complex was
generated using the x-ray structure of the human lymphotoxin a-TNF
receptor I complex (54). Three copies of the ligand model and three
copies of the receptor model were superimposed onto the corresponding
subunits of the experimental structure. The hexameric protein complex
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was further refined by 200 cycles of energy minimization with
CHARMM (53). The three N-glycosylation sites are located at Asn-184,
Asn-250, and Asn-260 in the FasL model. A short branched N-linked
glycan structure (GlcnAcb1–4Mana1–6[Mana1–3]Manb1–4GlcNAcb1
–4GlcNAc) was extracted from Brookhaven Protein Data Bank entry
9API, and was linked to the respective asparagines using interactive
graphics.
RESULTS AND DISCUSSION
Glycosylation of sFasL—A plasmid encoding the signal pep-
tide of hemaglutinin, in frame with a flag epitope and the
COOH-terminal portion of the extracellular domain of human
Fas ligand (amino acids 139–281), was transfected into the
human embryonic kidney 293 cell line. Secreted sFasL was
affinity-purified using immobilized anti-flag antibodies. The
theoretical molecular mass of the encoded recombinant protein
is 18.2 kDa. Purified sFasL migrated as a doublet on SDS-
PAGE with deduced molecular masses of 29 and 25.5 kDa (Fig.
1A). Taken together with previous data (55), this heterogeneity
and the discrepancy between predicted and observed molecular
masses suggest that carbohydrates are present on the sFasL.
Indeed, sFasL present in both cell extracts and cell superna-
tants could be digested with peptide N-glycanase F to a single
band with the predicted molecular mass of 18 kDa (Fig. 1B),
indicating that the various species of sFasL differed by their
degree of N-glycosylation. This result was confirmed when cells
were treated with the N-glycosylation inhibitor tunicamycin; a
dose-dependent accumulation of cellular, unglycosylated 18-
kDa sFasL was observed with concomitant loss of sFasL secre-
tion (Fig. 1C). A total of four evenly spaced bands of sFasL
could be detected, which probably correspond to the unglyco-
sylated, mono-, di-, and tri-N-glycosylated sFasL monomers.
Thus, all three potential N-glycosylation sites of human FasL
(Asn-184, Asn-250, and Asn-260) appear to be used. Interest-
ingly, secreted sFasL is consistently found in its highly glyco-
sylated form, even at intermediate tunicamycin concentrations
where unglycosylated sFasL is by far the predominant cellular
species (Fig. 1C). This strongly suggests that N-linked oligo-
saccharides are required for efficient secretion of sFasL.
We next generated a molecular model of the FasL-Fas com-
plex (Fig. 2) using knowledge-based protein modeling methods
and the known tridimensional structures of lymphotoxin a
FIG. 1. Glycosylation of sFasL. Panel A, Coomassie Blue staining
of sFasL. The flag-tagged sFasL in conditioned supernatants of stably
transfected 293 cells was affinity-purified on anti-flag M2 agarose, and
1.5 mg was analyzed by SDS-PAGE (12%) followed by Coomassie Blue
staining. The molecular mass markers (in kDa) are indicated. Panel B,
peptide N-glycanase F digestion of sFasL. 293 cells transiently trans-
fected with flag-tagged sFasL were grown for 72 h in serum-free me-
dium. Cell extracts (Cells, 2.5 3 105 cells/lane) and 20 3 concentrated
supernatant (S/N, 15 ml/lane) were treated with or without peptide
N-glycanase F (PNGase F) and analyzed by Western blotting using
anti-flag M2 antibodies. Panel C, the effect of tunicamycin on the
glycosylation and secretion of sFasL. Stably transfected 293 cells were
grown for 10 days in serum-free medium and in the presence of the
indicated concentrations of tunicamycin. Cells (2.5 3 105/lane) and
supernatants (20 ml) were analyzed by Western blotting using anti-flag
M2 antibodies.
FIG. 2. Molecular model of Fas-FasL interaction. Ribbon repre-
sentation of the Fas-FasL hexameric complex. The ligand monomers
are depicted in blue, while the receptor molecules are shown in light
green and disulfide bridges in yellow. The pink structures represent the
volume occupied by the nine N-linked glycans attached to Asn-184,
Asn-250, and Asn-260. N, Asn. A, top view of the complex; B, side view
of a simplified representation showing only subunit A of the Fas ligand
and its two bound receptor molecules. Transmembrane domains of Fas
and FasL would be at the top and at the bottom of the figure,
respectively.
FIG. 3. Sequence alignment of the COOH terminus of FasL and
of the loop DE region of TNF family members. Panel A, carboxyl-
terminal sequence of human and murine FasL showing the site of the
gld mutation (box). Numbering refers to the human FasL sequence.
Panel B, sequence alignment of various ligands around loop DE. The
conserved Tyr residue is boxed (position 218 in human FasL). Note that
this Tyr residue is not conserved in CD27L, CD30L, and CD40L.
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(TNFb) and the 55-kDa tumor necrosis factor receptor (49). It
can be seen that the N-linked oligosaccharides are concen-
trated on the lateral edge of each FasL monomer, leaving
vertical clefts, which would allow the receptor to reach the
interaction site of the ligand.
Two of the three glycosylation sites of the FasL have coun-
terparts in other family members. Residue Asn-260 of FasL is
also found at the corresponding position in lymphotoxin b,
CD27L, and CD40L, whereas residue Asn-250 of FasL corre-
sponds to a site in CD30L. In some TNF family members,
N-glycosylation appears to be important for the biological ac-
tivity of the protein. For example, FasL, which can be ex-
pressed in a variety of eukaryotic systems (20, 56, 57), forms
inactive inclusion bodies when expressed in bacteria.2 The ex-
tensively glycosylated CD30L (four putative N-glycosylation
sites) is also best produced in a recombinant form in eukaryotic
systems (57). Glycosylated recombinant CD40L is readily ex-
pressed at the surface of eukaryotic cells, but transport to the
cell surface is blocked in the presence of the N-glycosylation
inhibitor tunicamycin (57). In contrast, TNFa (58) and lympho-
toxin a (59) can be produced in a soluble, non-glycosylated and
active form in prokaryotic expression systems. When these two
latter ligands are expressed in eukaryotic systems, N-glycosy-
lation can result in minor effects such as a 10-fold decrease in
specific activity of TNFa (60) or the masking of epitopes recog-
nized by neutralizing antibodies for lymphotoxin a (61). This
supports the conclusion that N-glycosylation can be important
for the efficient secretion of FasL and other glycosylated li-
gands of this family.
The Mouse gld Mutation Also Renders Human sFasL Inac-
tive—The availability of an efficient system for the production
of recombinant sFasL allowed us to test the validity of the
structural model of the Fas-FasL by generating a number of
mutants (Fig. 3). A well characterized spontaneous mutation
(F273L) in murine FasL, called gld, abolishes FasL activity and
results in a phenotype of generalized lymphoproliferative dis-
ease (15). The mutant F275L was engineered to test whether
an analogous mutation would also inactivate human FasL (Fig.
3A). The yield of F275L sFasL secretion was low compared with
wild type sFasL, but its molecular weight suggested that it was
completely N-glycosylated (Fig. 4A, lane F275L). The F275L
mutation had a severe effect on the cytotoxic activity of sFasL,
which was reduced by more than 5 orders of magnitude com-
pared with wild type (Fig. 4B). These results raised the ques-
tion of whether the F275L mutant was properly folded and
trimerized. Therefore wild type and mutated FasL were ana-
lyzed by gel permeation chromatography. Wild type FasL
eluted as a defined peak with an apparent molecular mass of 79
kDa (corresponding to a 2.7-mer), whereas the F275L mutant
eluted broadly throughout the profile (Fig. 5). It is conceivable
that this mutation, occurring at the hydrophobic interface of
two monomers (62), prevents correct association of otherwise
properly folded monomers leading to uncontrolled association
and impairment of binding to Fas. Interestingly, FasL is nor-
mally expressed at the surface of activated T-lymphocytes from
gld mice (62), raising the question of whether the structural
impact of the gld mutation is less severe in the murine protein
as compared with human FasL.
Amino Acid Residues Pro-206 and Tyr-218 of FasL Are Im-
portant for the Interaction with Fas—Due to their predicted
close proximity to the receptor (Fig. 6), amino acids Pro-206
and Tyr-218 were chosen for mutagenesis. The mutants P206F,
P206D, and P206R were secreted and glycosylated (Fig. 4A),
and were between 100-fold (for P206F) and 500-fold (for
P206D) less active than wild type FasL (Fig. 4B). The binding
of the FasL to Fas was determined in vitro with a Fas-FasL2 P. Schneider, unpublished observation.
FIG. 4. Expression and cytotoxic activity of wild type and mu-
tant sFasL. Panel A, Western blot of concentrated supernatant from
transiently transfected 293T cells as detected by antibody staining with
the anti-flag M2 antibody. Ten-fold more supernatant of mutant F275L
was loaded to achieve a similar intensity of staining. wt, wild type.
Panel B, cytotoxic activity of sFasL mutants on murine and human
cells. Murine A20 cells (upper graphs) and human Jurkat cells (bottom
graphs) were incubated at 37 °C in the presence of the indicated con-
centrations of wild type or mutant sFasL, and of 1 mg/ml M2 antibody.
After 8 h, the phenazine methosulfate/MTS reagent was added, and the
incubation was carried out for an additional 4 h. The cell viability was
monitored at 490 nm. Open squares, wild type sFasL (wt); closed
squares, F275L; open circles, P206F; closed circles, P206D; open dia-
monds, P206R; closed diamonds, Y218F; open triangles, Y218D; closed
triangles, Y218R.
FIG. 5. Size exclusion chromatography of sFasL on Superdex-
200. Concentrated supernatants containing wild type or F275L “gld”
sFasL were fractionated on a Superdex-200 column. Eluted fractions
were analyzed by Western blotting and the sFasL detected with M2
antibody. The migration positions of the molecular mass markers (in
kDa) are indicated on the left hand side for SDS-PAGE and at the top
of the figure for size exclusion chromatography. The graph superim-
posed on the wild type elution profile (wt) represents the signal ob-
tained for 5 ml of each fraction in a hFas-Fc/FasL interaction ELISA, as
described in the legend to Fig. 7.
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interaction ELISA. In this assay, recombinant FasL is captured
by chimeric Fas-Fc coated on plastic, and the interaction is
detected by antibody binding to the flag epitope present at the
NH2 terminus of the sFasL (Fig. 7). The binding affinity was
strong for wild type FasL, weak yet significant for the Pro-206
mutants, and equal to background for the F275L “gld” mutant,
correlating with their respective potency to induce apoptosis in
target cells. These results suggest that the Pro-206 residue of
the FasL is directly involved in the Fas-FasL interaction, al-
though we cannot formally exclude that the observed pheno-
type is the result of the structural impact of the mutation on
FasL.
Tyr-218 is located in a loop between b-strands D and E of the
FasL (Figs. 3B and 6). This residue is conserved among a
number of ligands, including all known death-inducing ligands
(Fig. 3B). This is a remarkable feature, as loop residues are
normally highly variable between family members. Moreover,
this tyrosine residue is known to be essential for lymphotoxin a
(TNFb) and TNFa binding to TNF-receptor I (49, 59, 63).
Surprisingly, the Y218D mutant and the wild type FasL
have similar abilities to kill both murine and human target
cells (Fig. 4B) and to bind to recombinant Fas of both species
(Fig. 7B). This is, however, in sharp contrast with the Y218R
mutant, which is 4 orders of magnitude less active than wild
type FasL on murine cells, and which displays impaired bind-
ing to Fas (Figs. 4B and 7B). This latter mutant is, however,
very similar to wild type FasL by other criteria such as secre-
tion efficiency, glycosylation, and size as determined by gel
permeation chromatography (Fig. 4A and data not shown). The
region of Fas interacting with Tyr-218 is rich in basic amino
acid residues (Fig. 8). The phenol group of the tyrosine is
therefore likely to form hydrogen bonds with Fas, and could
even exist as phenolate in this environment to form a salt
bridge with Fas. In this context, changing the Tyr residue for a
negatively charged Asp residue can be considered as a conserv-
ative mutation. In contrast, mutation of the Tyr residue for a
positively charged Arg residue (Y218R) will not only disrupt
the existing interactions but will add a detrimental electro-
static repulsion leading to the observed greatly impaired cyto-
toxic phenotype.
FIG. 8. Molecular model of the Fas-FasL contact site in the
area of FasL Tyr-218. The ligand monomer is depicted in light green,
while the receptor molecule is shown in light yellow. Tyr-218 of FasL,
which was mutated to Phe, Asp, and Arg, is represented in red, while
residues bearing a positive charge and histidine are shown in blue.
Ser-83 of hFas is an Asp-74 residue in muFas.
FIG. 6. Location of Pro-206 and Tyr-218 of FasL in the struc-
tural model of Fas-FasL. A single ligand subunit and a single recep-
tor are shown.
FIG. 7. Fas-FasL interaction measured by ELISA. The extracel-
lular domains of murine (panels A and B) or human (panel C) Fas fused
to the Fc portion of a human IgG1 were coated on immunoplates and
used to capture wild type (wt) or mutant human sFasL. Bound sFasL
was detected using the M2 antibody and an anti-mouse peroxidase
conjugate. In panel A, wild type and mutated sFasL were used at a
single concentration of 200 ng/ml. In panels B and C, selected sFasL
(wild type and the Tyr-218 mutants) were used at the indicated
concentrations.
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It has been shown recently that the amino acid residue
Arg-86 (but not Lys-78) of Fas is essential for ligand binding
(64). Taken together with our results, this suggests that a
strong interaction takes place between Tyr-218 of FasL and
Arg-86 of Fas (Fig. 8).
The Y218F sFasL Mutant Specifically Interacts with Murine
but Not Human Fas—The effect of the Y218F mutation on
sFasL should be intermediate between that seen for the Y218D
and Y218R mutations described above, since the positive inter-
action of the phenol group of Tyr-218 with Fas should be lost
without generating additional repulsion. As expected from this
model, the Y218F mutant of FasL displays intermediate cyto-
toxic activity (Fig. 4B). Interestingly, the cytotoxic effect of this
mutant is markedly dependent upon the species from which the
receptor derives, which is in contrast with the documented
complete cross-reactivity between wild type human and murine
FasL and Fas (38). The Y218F mutant is relatively potent at
killing murine target cells and is apparently inactive on human
target cells (Fig. 4B). This species specificity is also evident at
the level of recombinant Fas binding (Fig. 7). This suggests
that the binding of the sFasL to murine Fas relies on more
frequent, or more stable interactions than to human Fas. De-
stroying the Tyr-218 interaction site is therefore less detrimen-
tal for murine Fas binding activity than for human Fas. A list
of Fas residues, which are likely to be involved in FasL binding
but which are different between both species, is given in Table
I. This difference in activity between murine and human Fas
was not due to the presence of an Asp-74 in murine Fas instead
of a Ser-83 in human Fas (Table I and data not shown). Similar
effects of specificity restriction have been observed in TNFa,
where point mutations induced marked specificity for either
TNF-R1 or TNF-R2 (58).
If the Y218F sFasL mutant is species-specific, it should be
able to exert its cytotoxic effect on murine target cells even in
the presence of an excess of soluble recombinant human Fas,
but should be inhibited by recombinant murine Fas. In con-
trast, wild type sFasL should be inhibited by recombinant Fas
from both species. To confirm this point, murine target cells
were exposed to a lethal dose of either wild type or Y218F
sFasL, in the presence of increasing amounts of recombinant
human or murine Fas-Fc fusion proteins (Fig. 9). As predicted,
Y218F sFasL was inhibited by murine Fas-Fc but left practi-
cally unaffected by human Fas-Fc. In contrast, wild type sFasL
was inhibited by both fusion proteins (Fig. 9). This experiment
demonstrates the strong (however not absolute) species speci-
ficity of Y218F sFasL toward murine Fas.
In summary, we have found that the N-glycosylation of
sFasL is required for its solubility, and we describe a method
for its production and purification. The availability of sFasL
(and its inhibitor Fas-Fc) will prove useful to study a variety of
systems in which Fas and FasL are implicated. In addition, the
model that we presented here allowed us to successfully design
mutations affecting the binding of FasL to Fas, and should
therefore facilitate the design of specific inhibitors of Fas-FasL
inhibitors.
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